Congress Materials – Digestive Disease Week (DDW 2025)
2025 Digestive Disease Week | May 3-6 | San Diego, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Characterization of Serum Inflammatory Proteins in Response to guselkumab or ustekinumab Induction and Maintenance Dosing in Moderately to Severely Active Crohn’s Disease: Analysis of GALAXI Ph3
Dylan J Richards, Jared Liu, Martha Zeeman, Natalie A Terry, Marion Vetter, Daniel Cua, Tom C. Freeman, Bradford Mcrae, Walter Reinisch, Patrick Branigan
Comorbidities and Extraintestinal Manifestations Among Patients with Difficult-to-Treat Inflammatory Bowel Disease in Latin America
Domingo Balderramo, Fabian Juliao-Baños, Cristina Flores, Renata Fróes, Jesús Kazuo Yamamoto-Furusho, Guillermo Veitia, Tarcia Gomes, Socrates Bautista Martinez, Norma Nathaly Parra Holguín, Beatriz Iade, Fabio Azevedo, Jaqueline Saes, Amanda Yaeza Ferreira, Juan Sebastian Lasa
Comparison Of Pharmacodynamic And Mechanistic Response Of Guselkumab Subcutaneous And Intravenous Induction In Moderately To Severely Active Crohn’S Disease: Molecular Analysis Of The GRAVITI And GALAXI Phase 3 Studies
Dylan J Richards, Ruchi Patel, Klebea Sohn, Amy Hart, Tae Lee, Jared Liu, Christopher Sisk, Mobolaji Olurinde, Natalie A Terry, Bradford Mcrae, Walter Reinisch, Brian G. Feagan, Flavio Steinwurz, Remo Panaccione, Geert D’Haens, Patrick Branigan
Corticosteroid Sparing Effects Of Treatment With Guselkumab In Patients With Moderate To Severely Active Crohn’S Disease: Phase 3 GALAXI 2/3 Results Through Week 48
Julián Panés, Tadakazu Hisamatsu, Alessandro Armuzzi, Natalie A Terry, Leonardo Salese, Rian Van Rampelbergh, Jacqueline Yee, Kitty Yuen Yi Wan, Zijiang Yang, Scott Pin, Bruce E. Sands, David T. Rubin
Corticosteroid Sparing Effects Of Treatment With Guselkumab In Patients With Moderately To Severely Active Crohn’s Disease: Phase 3 GRAVITI Study Results Through Week 48
Ailsa Hart, Remo Panaccione, Flavio Steinwurz, Qian Cao, Tadakazu Hisamatsu, Stephane Nancey, Mobolaji Olurinde, Zijiang Yang, Elizabethe Merrall, Natalie A. Terry, Bruce E. Sands
Early Disease Efficacy Of Guselkumab Therapy In Biologic-Naïve Patients With Moderately To Severely Active Crohn’S Disease: Post-Hoc Analysis From The Phase 3 GALAXI 2 & 3 Studies
Anita Afzali, David T. Rubin, Silvio Danese, Yaser Rayyan, Minhu Chen, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Jacqueline Yee, Mario Gomez, Kitty Yuen Yi Wan, Zijiang Yang, Bruce E. Sands, Geert D’Haens
Efficacy And Safety Of Guselkumab For Ulcerative Colitis Through Week 92 Of The QUASAR Long-Term Extension Study
Gary Roth Lichtenstein, Jessica R. Allegretti, David T. Rubin, Brian G. Feagan, Brian Bressler, Julián Panés, Waqqas Afif, Mark Samaan, Byong Duk Ye, Shadi Yarandi, Matthew Germinaro, Nicole Shipitofsky, Ye Miao, Pankaj Mistry, Hongyan Zhang, Axel Dignass, Bruce E. Sands, Tadakazu Hisamatsu, Laurent Peyrin-Biroulet
Efficacy And Safety Of Subcutaneous Guselkumab Induction Therapy In Patients With Ulcerative Colitis: Results Through Week 24 From The Phase 3 ASTRO Study
Millie Dascomb Long, Jessica R. Allegretti, Silvio Danese, Matthew Germinaro, Thomas Baker, Yelina Alvarez, Silke Jörgens, Lingjing Jiang, Hongyan Zhang, Tadakazu Hisamatsu, David T. Rubin, Laurent Peyrin-Biroulet
Efficacy Of Guselkumab Intravenous And Subcutaneous Induction: Symptoms, Health-Related Quality Of Life, And Inflammatory Biomarker Results From The GALAXI And GRAVITI Studies
Anita Afzali, Remo Panaccione, Silvio Danese, Tadakazu Hisamatsu, Geert D’Haens, Natalie A Terry, Mobolaji Olurinde, Rian Van Rampelbergh, Leonardo Salese, Elizabethe Merrall, Kitty Yuen Yi Wan, Zijiang Yang, Bruce E. Sands, Ailsa Hart
Efficacy of Subcutaneous Guselkumab Induction Therapy by Baseline Demographics and Concomitant Medications in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study
Ailsa Hart, Tadakazu Hisamatsu, Flavio Steinwurz, Geert D’Haens, Wenjia Liu, Mobolaji Olurinde, Phumla Ngqawa, Zijiang Yang, Elizabethe Merrall, Natalie A Terry, Remo Panaccione, Bruce E. Sands
Efficacy, Safety, And Pharmacokinetics Of Golimumab In Pediatric Patients With Moderately-To-Severely Active Ulcerative Colitis: Results From The Phase 3 Open-Label PURSUIT 2 Study
Dan Turner, Kathleen G. Lomax, Gigi Veereman, Anne Marie Griffiths, Jaroslaw Kierkus, Ben Kang, Katherine Berezny, Lakshmi Padgett, Gary Mao, Yevgeny Zitser, Richard Strauss, Jeroen Verhoeven, Omoniyi J. Adedokun, Jeffrey Samuel Hyams
Endoscopic Patient Clustering To Investigate Differential Treatment Effects Of Guselkumab And Ustekinumab In Crohn'S Disease: Post-Hoc Analysis Of GALAXI And GRAVITI Trials
Dylan J. Richards, Loqmane Seridi, Klebea Sohn, Bradford Mcrae, Natalie A. Terry, Marion Vetter, Daniel Cua, Patrick Branigan, Walter Reinisch, Raja Atreya
Five-Year Clinical Outcomes And Disease Course Of Newly-Diagnosed Moderate-To-Severe Ulcerative Colitis: A Prospective Nationwide Multicenter Mosaik Cohort Study In Korea
Byong Duk Ye, Hyo Jong Kim, Dongil Park, Young Sook Park, Kang-Moon Lee, Jong Pil Im, Sung-Ae Jung, Yoon Tae Jeen, Jae Myung Cha, Jae Hee Cheon, Sung Noh Hong, Youngdoe Kim, Jong Min Choi, YoungJa Lee, Chang Kyun Lee
Guselkumab Induction Therapy Results In Molecular Resolution Of Inflammation In Moderately To Severely Active Ulcerative Colitis: Results From The Phase 3 QUASAR Induction Study
Sunandini Sridhar, Amy Hart, Swati Venkat, Kuan-Hsiang Gary Huang, Shadi Yarandi, Matthew Germinaro, Marion Vetter, David T. Rubin, Axel Dignass, Daniel Cua, Tom C. Freeman, Dawn M Waterworth, Bradford Mcrae, Bram Verstockt, Patrick Branigan
Guselkumab Maintenance Therapy Mediates Further Improvements In Intestinal Immune Homeostasis And Mucosal Healing In Patients With Ulcerative Colitis
Amy Hart, Sunandini Sridhar, Swati Venkat, Kuan-Hsiang Gary Huang, Shadi Yarandi, Matthew Germinaro, Marion Vetter, David T. Rubin, Axel Dignass, Daniel Cua, Tom C. Freeman, Dawn M Waterworth, Bradford Mcrae, Bram Verstockt, Patrick Branigan
Longitudinally Collected Physiological Data From Wearable Devices Identifies Inflammatory Activity Following Biologic Initiation
Robert P. Hirten, Rana Zia Ur Rehman, Matteo Danieletto, Meenakshi Chatterjee, Molly Lucas, Drew Helmus, Nikolay Manyakov, Tim Hewitt, Yanran Huo, Dylan Schorr, Saiyam Jain, Tiffany Lontoc, Michael Deman, Vasanth Thirugnanam, Bruce E. Sands and Mark Morris
Safety Of Guselkumab In Inflammatory Bowel Disease Up To 1 Year: Integrated Safety Analysis Of Phase 2 And 3 Studies In Crohn’S Disease And Ulcerative Colitis
Bruce E. Sands, Remo Panaccione, Silvio Danese, Julián Panés, Tadakazu Hisamatsu, Geert D’Haens, Rian Van Rampelbergh, Mobolaji Olurinde, Jacqueline Yee, Thomas Baker, Shadi Yarandi. Matthew Germinaro, Marion Vetter, Hewei Li, Mauricio Rosas Ballina, Jessica R. Allegretti, Anita Afzali, David T. Rubin
The Impact Of Disease Status After Biologic Induction Therapy On Long-Term Outcomes In Persons With Crohn'S Disease
Gurmun Singh Brar, Parul Tandon, , Muzzafar Haque, Nazish Butt, Myrlene Sanon, Dominik Naessens, Eneda Pone, Laura Targownik
Treatment Discontinuation in Patients with Ulcerative Colitis or Crohn’s Disease Receiving Biologic Therapies that Require Intravenous Infusions during Induction and Subcutaneous Injections during Maintenance
Jennifer Seminerio, Yichen Zhang, Yan Wang, Aolin Wang, Shuang Wang, Christopher Busse, Sheetal P. Dharia, Gustavo Scapini, Xiaoxiao Lu, Ryan C Ungaro
Ulcerative Colitis-Related Medical Encounters In Patients Treated With Guselkumab: An Analysis of the QUASAR Phase 3 Induction Study
Elise Wu, Sumesh Kachroo, Ye Miao, Gustavo Scapini, Shadi Yarandi
Ustekinumab Open-label Induction and Randomized Blinded Maintenance Therapy in Pediatric Participants with Moderately to Severely Active Crohn’s Disease: the Phase 3 UNITI Jr study
Elisabeth de Greef, Richard Strauss, Els Van Limbergh, Stanley A. Cohen, Dan Turner, Anne Marie Griffiths, Jeffrey Samuel Hyams, Joel R. Rosh, Omoniyi J. Adedokun, Lilianne Kim, Sheri Volger
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.